Clinical Trials

18 enrolled

Head & Neck

Thyroid Neoplasms

NCT07509034 2026-06-05

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

40 enrolled

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT07524530 2026-06-05

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

LymphoidOther hematologic neoplasm

98 enrolled

Leukemia, Lymphoma, Hematologic Neoplasms

NCT07572136 2026-06-05

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

LymphoidOther hematologic neoplasm

57 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07574541 2026-06-05

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

52 enrolled

Genitourinary

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

NCT07169617 2026-06-03

Testing the SurVaxM Vaccine for Lung Cancer Prevention

80 enrolled

Thoracic

Lung Neoplasms

NCT07504588 2026-06-03

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

87 enrolled

Gynecologic

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07619521 2026-06-02

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

31 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02522611 2026-06-01

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

30 enrolled

Cancer Pain, Pain, Intractable

NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Other hematologic neoplasmPlasma cell

74 enrolled

Leukemia, Plasma Cell

NCT07516366 2026-05-15

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

16 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07551596 2026-05-15

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

20 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07349641 2026-05-14

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

55 enrolled

Gynecologic

Endometrial Hyperplasia

NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

64 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT06948084 2026-05-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

80 enrolled

Plasma cell

Multiple Myeloma

NCT06954987 2026-05-13

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Other hematologic neoplasm

244 enrolled

Leukemia, Myeloid, Acute

NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

BreastGenitourinaryThoracic

24 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT07153497 2026-05-13

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

MyeloidOther hematologic neoplasm

132 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07332507 2026-05-13

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

Phase 3 Not yet recruiting

30 enrolled

Lymphoid

Plasmablastic Lymphoma

NCT07388524 2026-05-13

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

336 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

30 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT07437950 2026-05-13

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Other hematologic neoplasm

126 enrolled

Leukemia, Myeloid, Acute

NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

NCT07463807 2026-05-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

162 enrolled

Plasma cell

Multiple Myeloma

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

76 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT05554419 2026-04-13

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)